A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
ClinicalTrials.gov · NCT07923357 · Registry updated: 2026-11-06
- Condition / research focus
- Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2026-10-30. Completion: 2027-11-30 (may be estimated). No results posted in this registry response.
Products and interventions (7)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- SAL0150 dose 1 (drug)
- SAL0150 dose 2 (drug)
- SAL0150 dose 2 (drug)
- SAL0150 dose 3 (drug)
- SAL0150 dose 3 (drug)
- Placebo (drug)
- Semaglutide inject 1.0 mg (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.